Linda C. Bain is a Venture Partner at Atlas Venture and also serves on the Boards of Arvinas, Autolus Therapeutics, and Remix Therapeutics. Previously, she was Chief Operating Officer and Chief Financial Officer at Mariana Oncology, where she led the company through its acquisition by Novartis in 2024. Earlier in her career, she served as CFO of Codiak BioSciences and held senior finance and operating roles at Adverum Biotechnologies (formerly Avalanche Biotechnologies), bluebird bio, Genzyme, Fidelity Investments, and AstraZeneca. A champion of health equity, Ms. Bain brings deep experience and perspective to Hemab’s mission to deliver transformative therapies to underserved patient communities. She earned her BS and Honors degrees in Accounting and Business Administration from the University of the Free State, South Africa.